A detailed history of Legal & General Group PLC transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 2,581 shares of ELYM stock, worth $10,607. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,581
Previous 2,581 -0.0%
Holding current value
$10,607
Previous $13,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.98 - $8.93 $9,711 - $17,413
1,950 Added 309.03%
2,581 $13,000
Q2 2024

Aug 14, 2024

BUY
$2.6 - $10.2 $1,640 - $6,436
631 New
631 $4,000
Q3 2022

Nov 14, 2022

SELL
$2.72 - $3.97 $1,523 - $2,223
-560 Closed
0 $0
Q2 2022

Aug 22, 2022

SELL
$2.77 - $8.4 $274 - $831
-99 Reduced 15.02%
560 $2,000
Q3 2021

Nov 15, 2021

BUY
$14.45 - $28.61 $9,522 - $18,853
659 New
659 $12,000

Others Institutions Holding ELYM

About Eliem Therapeutics, Inc.


  • Ticker ELYM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,567,700
  • Market Cap $109M
  • Description
  • Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...
More about ELYM
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.